JP2022505647A5 - - Google Patents

Info

Publication number
JP2022505647A5
JP2022505647A5 JP2021522061A JP2021522061A JP2022505647A5 JP 2022505647 A5 JP2022505647 A5 JP 2022505647A5 JP 2021522061 A JP2021522061 A JP 2021522061A JP 2021522061 A JP2021522061 A JP 2021522061A JP 2022505647 A5 JP2022505647 A5 JP 2022505647A5
Authority
JP
Japan
Prior art keywords
drawings
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021522061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505647A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/057672 external-priority patent/WO2020086724A1/en
Publication of JP2022505647A publication Critical patent/JP2022505647A/ja
Publication of JP2022505647A5 publication Critical patent/JP2022505647A5/ja
Priority to JP2025116644A priority Critical patent/JP2025148465A/ja
Pending legal-status Critical Current

Links

JP2021522061A 2018-10-23 2019-10-23 腫瘍の処置方法 Pending JP2022505647A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025116644A JP2025148465A (ja) 2018-10-23 2025-07-10 腫瘍の処置方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749393P 2018-10-23 2018-10-23
US62/749,393 2018-10-23
PCT/US2019/057672 WO2020086724A1 (en) 2018-10-23 2019-10-23 Methods of treating tumor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025116644A Division JP2025148465A (ja) 2018-10-23 2025-07-10 腫瘍の処置方法

Publications (2)

Publication Number Publication Date
JP2022505647A JP2022505647A (ja) 2022-01-14
JP2022505647A5 true JP2022505647A5 (cg-RX-API-DMAC7.html) 2022-11-01

Family

ID=68542836

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522061A Pending JP2022505647A (ja) 2018-10-23 2019-10-23 腫瘍の処置方法
JP2025116644A Pending JP2025148465A (ja) 2018-10-23 2025-07-10 腫瘍の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025116644A Pending JP2025148465A (ja) 2018-10-23 2025-07-10 腫瘍の処置方法

Country Status (5)

Country Link
US (2) US12479917B2 (cg-RX-API-DMAC7.html)
EP (1) EP3870609A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022505647A (cg-RX-API-DMAC7.html)
CN (1) CN112912403A (cg-RX-API-DMAC7.html)
WO (1) WO2020086724A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US11072657B2 (en) * 2015-11-18 2021-07-27 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
CN114720688B (zh) * 2022-06-08 2022-09-06 中国医学科学院肿瘤医院 肺癌免疫联合化疗药效预测EVs膜蛋白标志物
US20250376525A1 (en) * 2022-06-28 2025-12-11 Qilu Pharmaceutical Co., Ltd. Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof
EP4310197A1 (en) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
TWI826081B (zh) * 2022-10-28 2023-12-11 臺北醫學大學 癌症進展評估方法及其系統
CN116173059B (zh) * 2022-12-16 2024-11-05 福州载基生物科技有限公司 人aurkb基因在制备抗肿瘤药物中的用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
JP2017515859A (ja) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
CA2971734C (en) 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
WO2016191751A1 (en) * 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
JP6745870B2 (ja) 2015-08-14 2020-08-26 華為技術有限公司Huawei Technologies Co.,Ltd. アップリンク制御情報を送信するための方法および装置
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
JP7082051B2 (ja) 2016-01-11 2022-06-07 アルモ・バイオサイエンシーズ・インコーポレイテッド 抗原特異的cd8+t細胞の産生におけるインターロイキン-10及びその使用方法
EP3402255B1 (en) 2016-02-02 2021-03-31 Huawei Technologies Co., Ltd. Emission power verification method, user equipment, and base station
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017210631A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
EP3601355A1 (en) 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
EP3694884A1 (en) * 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
EP3774911A1 (en) * 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor

Similar Documents

Publication Publication Date Title
JP2024023385A5 (cg-RX-API-DMAC7.html)
JP2021169491A5 (cg-RX-API-DMAC7.html)
JP2020127044A5 (cg-RX-API-DMAC7.html)
JP2022028828A5 (cg-RX-API-DMAC7.html)
JP2022025124A5 (cg-RX-API-DMAC7.html)
JP2021185136A5 (cg-RX-API-DMAC7.html)
JP2022523200A5 (cg-RX-API-DMAC7.html)
JP2021512414A5 (cg-RX-API-DMAC7.html)
JP2020127428A5 (cg-RX-API-DMAC7.html)
JP2021503478A5 (cg-RX-API-DMAC7.html)
JP2021500894A5 (cg-RX-API-DMAC7.html)
JP2020042034A5 (cg-RX-API-DMAC7.html)
JP2019099571A5 (cg-RX-API-DMAC7.html)
JP2019536002A5 (cg-RX-API-DMAC7.html)
JP2021038271A5 (cg-RX-API-DMAC7.html)
JP2021518389A5 (cg-RX-API-DMAC7.html)
JP2021502066A5 (cg-RX-API-DMAC7.html)
JP2019030304A5 (cg-RX-API-DMAC7.html)
JP2019031552A5 (cg-RX-API-DMAC7.html)
JP2018154848A5 (cg-RX-API-DMAC7.html)
JP2024016014A5 (cg-RX-API-DMAC7.html)
JP2022060295A5 (cg-RX-API-DMAC7.html)
JP2021524864A5 (cg-RX-API-DMAC7.html)
JP2018135352A5 (cg-RX-API-DMAC7.html)
JP2020171301A5 (cg-RX-API-DMAC7.html)